Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

67.24 -0.27 (-0.40%)
Official Closing Price Updated: 7:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
34 35 Next >
Bristol Myers Squibb Announces Dividend Increase and Additional $15 Billion Share Repurchase Authorization
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Reveals Full Data For Breyanzi In Second-Line Lymphoma Setting
Bristol Myers Squibb & Co (NYSE: BMY) released the first disclosure of results from a prespecified interim analysis of Phase 3 TRANSFORM study of Breyanzi... 
Via Benzinga
The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More
Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound. Multiple... 
Via Benzinga
Exposures Product Safety
5 Dividend Growth Stocks Getting Crushed… Time To Buy?
We have a disconnect between business performance and stock performance. And we have a disconnect between individual stocks and the stock market. These disconnects could lead us to fantastic long-term... 
Via Talk Markets
Tomorrow's Innovators: Kwame Sarpong
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
Sunday Memo - Dec. 5
The market rout was worldwide last week. 
Via Talk Markets
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) Significantly Improves Outcomes, Showing Superiority Over 20-Year Standard of Care in Second-Line Relapsed or Refractory Large B-cell Lymphoma Based on TRANSFORM Study Results
From Bristol Myers Squibb
Via Business Wire
Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel... 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Infinity Pharma Shares Updated Eganelisib Combo Therapy In Breast Cancer Trial
Infinity Pharmaceuticals Inc (NASDAQ: INFI) presented updated data from the ongoing MARIO-3 study during the 2021 San Antonio Breast Cancer Symposium (SABCS).... 
Via Benzinga
Why You Should Buy Moderna Stock at Every Dip
Moderna’s cash growth will continue as demand for booster shots and vaccines for the omicron variant increase, giving a boost to MRNA stock. 
Via InvestorPlace
Exposures COVID-19
Omicron Surge
The seemingly good level of joblessness at a mere 184,000 turns out to be less wonderful than it appears, at the lowest since 1969. 
Via Talk Markets
Where Bristol-Myers Squibb Stands With Analysts
Analysts have provided the following ratings for Bristol-Myers Squibb (NYSE:BMY 
Via Benzinga
How Did Healthcare Stocks Perform Over This Volatile Month?
It’s been a rough month for small-cap biotech stocks amidst a general correction in the market which brought general indices down about 10%. 
Via Talk Markets
A great example of stopping volume on the Bristol-Myers Squibb daily stock chart
We have seen the stock rally from the lows of $53 per share back to $57 per share over the last few days. 
Via Talk Markets
Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021
Upgrades According to BMO Capital, the prior rating for Nuvei Corp (NASDAQ: 
Via Benzinga
Could Bristol Myers Squibb and Johnson & Johnson Have a Powerful New Blood Thinner on the Way?
It's still early, but so far so good. 
Via The Motley Fool
BRISTOL MYERS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against Bristol-Myers Squibb Company - BMY
From Kahn Swick & Foti, LLC
Via Business Wire
Charms Of China
Today the global stock market rout was pretty awful. 
Via Talk Markets
Bristol Myers - Merck's Thalassemia Candidate Under FDA Priority Review
The FDA has accepted for review Bristol Myers Squibb Co's (NYSE: BMY) supplemental application seeking approval for Reblozyl (luspatercept-aamt) in adults with... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases... 
Via Benzinga
U.S. Food and Drug Administration Accepts for Priority Review supplemental Biologics License Application for Reblozyl® (luspatercept-aamt) in Adults with Non-Transfusion Dependent (NTD) Beta Thalassemia
From Bristol Myers Squibb
Via Business Wire
AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today
Aurinia Pharma (AUPH) stock is on the rise Thursday as investors hold out hope for a takeover of the company by Novartis (NVS). 
Via InvestorPlace
Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates
A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for... 
Via Benzinga
Exposures Product Safety
Encouraging Recruitment of Diverse Talent in the Biopharma Industry
SOURCE: Bristol Myers Squibb Company 
Via 3BL Media
Topics Supply Chain
Exposures Supply Chain
7 Drug Stocks to Buy Now While They’re Still on Sale
Covid-19 stocks soared to unsustainable highs as investors ignored drug stocks with a deep pipeline of products for the decade ahead. 
Via InvestorPlace
Topics Supply Chain
Exposures COVID-19 Supply Chain
Mereo BioPharma's Etigilimab/Opdivo Combo Achieves One Complete Response In Cervical Cancer
Mereo BioPharma Group plc (NASDAQ: MREO) reported interim data from ACTIVATE Phase 1b/2 study of its anti-TIGIT antibody, etigilimab, in combination with ... 
Via Benzinga
Better Pharma Stock: GlaxoSmithKline vs. Bristol-Myers Squibb
They're very similar companies on the surface, but one is planning for a big disruption. 
Via The Motley Fool
Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ: 
Via Benzinga
Warren Buffett Is Selling These Stocks
Looking to make money moves like Warren Buffett? Want to know which stocks Buffett is selling? Interested in finding out why these stock sales might be a huge mistake? 
Via Talk Markets
Bristol Myers Squibb Co Drops Again, Here’s The Trade
The next major support level for Bristol Myers Squibb Co stock will be around the $50.00 area. This level is where the stock reversed a big downside decline in March 2020. 
Via Talk Markets
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
34 35 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.